“Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s617. https://doi.org/10.25251/gf6mb511.